ArticleHealth science reports2026
The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches-A Narrative Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Neuroblastoma is the most common extracranial solid tumor and contributes the most to pediatric oncology deaths worldwide. Its clinical manifestations are heterogeneous, including relapses, and the prognosis remains poor, especially for high-risk patients. The principal interventions-surgery, chemotherapy, and radiotherapy-exacerbate the prognosis due to high morbidity and poor long-term remission rates. This study attempts to integrate available information on the genetic and molecular characteristics of neuroblastoma, focusing on how the potential of precision medicine is improving neuroblastoma diagnosis and treatment. Methods: This review aims to compile recent literature on the genomic, transcriptomic and epigenetic studies of neuroblastoma and its treatment. The review included the most recent molecular markers for the relevant pathway, the therapeutic targets that arise from them and precision medicine approaches that incorporate AI, CRISPR, and neoantigen vaccines at various stages of clinical trials. Results: Targeted medicines such MYCN amplification, ALK mutations, and chromosomal deletions including 1p36 and 11q have revealed important genetic drivers of neuroblastoma. Early-phase studies have shown encouraging reductions in tumor progression with MYCN modulators, ALK inhibitors and immunotherapies (anti-GD2 antibodies, B7-H3 CAR-T cells). Integrating omics-based markers and AI-directed therapy prediction more precisely classifies risk and customizes therapy. Conclusion: Precision medicine has transformed neuroblastoma treatment by improving diagnostic specificity and therapeutic effectiveness while reducing toxicity. Among emerging strategies, ALK-targeted therapies and anti-GD2 immunotherapies show strong clinical potential, although further validation is still required to improve survival and quality of life in affected children.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.